Department of Neurosurgery, New York University Langone Medical Center, New York, New York, USA.
World Neurosurg. 2011 Jul-Aug;76(1-2):128-40; discussion 61-2. doi: 10.1016/j.wneu.2010.12.053.
To review the authors' experience with Gamma Knife radiosurgery (GKR) for small recurrent high-grade gliomas (HGGs) following prior radical resection, external-beam radiation therapy (EBRT), and chemotherapy with temozolomide (TMZ).
The authors retrospectively analyzed 26 consecutive adults (9 women and 17 men; median age 60.4 years; Karnofsky Performance Status [KPS]≥70) who underwent GKR for recurrent HGGs from 2004-2009. Median lesion volume was 1.22 cc, and median treatment dose was 15 Gy. Pathology included glioblastoma multiforme (GBM; n=16), anaplastic astrocytoma (AA; n=5), and anaplastic mixed oligoastrocytoma (AMOA; n=5). Two patients lost to follow-up were excluded from radiographic outcome analyses.
Median overall survival (OS) for the entire cohort from the time of GKR was 13.5 months. Values for 12-month actuarial survival from time of GKR for GBM, AMOA, and AA were 37%, 20% and 80%. Local failure occurred in 9 patients (37.5%) at a median time of 5.8 months, and 18 patients (75%) experienced distant progression at a median of 4.8 months. Complications included radiation necrosis in two patients and transient worsening of hemiparesis in one patient. Multivariate hazard ratio (HR) analysis showed KPS 90 or greater, smaller tumor volumes, and increased time to recurrence after resection to be associated with longer OS following GKR.
GKR provided good local tumor control in this group of clinically stable and predominantly high-functioning patients with small recurrent HGGs after radical resection. Meaningful survival times after GKR were seen. GKR can be considered for selected patients with recurrent HGGs.
回顾作者对先前行根治性切除术、外照射放疗(EBRT)和替莫唑胺(TMZ)化疗后复发的小体积高级别胶质瘤(HGG)患者行伽玛刀放射外科手术(GKR)的经验。
作者回顾性分析了 2004 年至 2009 年期间 26 例连续接受 GKR 治疗复发性 HGG 的成年人(9 名女性和 17 名男性;中位年龄 60.4 岁;卡氏功能状态评分[KPS]≥70)。中位病变体积为 1.22cc,中位治疗剂量为 15Gy。病理包括多形性胶质母细胞瘤(GBM;n=16)、间变性星形细胞瘤(AA;n=5)和间变性混合少突胶质细胞瘤(AMOA;n=5)。2 例失访患者被排除在影像学结果分析之外。
从 GKR 时间开始,整个队列的中位总生存期(OS)为 13.5 个月。GBM、AMOA 和 AA 患者从 GKR 时间开始的 12 个月生存率分别为 37%、20%和 80%。9 例(37.5%)患者在中位 5.8 个月时出现局部失败,18 例(75%)患者在中位 4.8 个月时出现远处进展。并发症包括 2 例放射性坏死和 1 例偏瘫短暂加重。多变量风险比(HR)分析表明,KPS 90 或更高、肿瘤体积更小以及切除后复发时间延长与 GKR 后 OS 延长相关。
在一组临床稳定且功能主要良好的小体积复发性 HGG 患者中,GKR 提供了良好的局部肿瘤控制。在 GKR 后观察到有意义的生存时间。对于复发性 HGG 患者,可以考虑 GKR。